Summary:
Click image to enlarge
Local researchers at Jubilee Clinical Research are enrolling adult participants into the ESSENCE study, investigating if the drug called semaglutide can slow or reverse NASH (damage from fatty liver) to a less severe stage. Previous clinical studies suggest that semaglutide can be beneficial for patients with NASH, and semaglutide is approved in many countries at a lower dose to treat type 2 diabetes.
Qualified Participants Must:
• Be 18 years of age of order
•
Have already had a liver biopsy confirming NASH or are willing to have one
•
Be able to attend regular clinic visits and receive phone calls over a period of up to 5 years
Qualified Participants May Receive:
There is no cost to participate and health insurance is not required to participate. Eligible participants may receive compensation for study participation.